U.S. Markets open in 6 hrs 15 mins
  • Gold

    1,780.20
    +14.50 (+0.82%)
     
  • EUR/USD

    1.1652
    +0.0034 (+0.2913%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • Vix

    16.31
    +0.01 (+0.06%)
     
  • GBP/USD

    1.3774
    +0.0047 (+0.3444%)
     
  • USD/JPY

    114.0600
    -0.2520 (-0.2204%)
     
  • BTC-USD

    62,192.41
    -203.64 (-0.33%)
     
  • CMC Crypto 200

    1,450.98
    -0.66 (-0.05%)
     
  • FTSE 100

    7,218.33
    +14.50 (+0.20%)
     
  • Nikkei 225

    29,215.52
    +190.06 (+0.65%)
     

Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear DMPK RNA, the genetic basis of the disease.

  • Data were presented at the American Society of Gene & Cell Therapy Annual Meeting.

  • Data showed reductions in toxic human nuclear DMPK RNA with twice the duration and half the dose compared to the data reported in January of this year.

  • In January 2021, Dyne reported data showing that two doses (2 x 10 mg/kg) of its lead DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days.

  • New data demonstrated an approximately 405 reduction in DMPK heart foci at 14 days.

  • Dyne expanded its analysis with a single, low 10 mg/kg dose. These new data show sustained DMPK knockdown at four weeks: 51% in the diaphragm, 46% in both the heart and tibialis anterior, and 42% in the gastrocnemius.

  • DM1 is a rare, progressive, genetic disease that affects skeletal, cardiac, and smooth muscles. It is caused by an abnormal expansion in a region of the DMPK gene.

  • Price Action: DYN shares are trading 3.7% higher at $17.61 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.